Wellcome Trust Sanger Institute-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013427)
◆英語タイトル:Wellcome Trust Sanger Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013427
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:38
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research and the clinical applications of genomics in human and infectious disease. Sanger Institute works in collaboration with academic, industrial, biotech and pharmaceutical industries for national and international projects. It is funded by Wellcome Trust, UK Research Councils, Charities, the EU and NIH. The institute has facilities for protein mass spectrometry, fluorescence activated cell sorting and cytogenetics and single cell genomics. Sanger Institute is headquartered in Hinxton, the UK.

Wellcome Trust Sanger Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Wellcome Trust Sanger Institute, Medical Devices Deals, 2011 to YTD 2017 9
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Sigma-Aldrich Enters into Agreement with Sanger Institute 11
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 12
Licensing Agreements 13
Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 13
Equity Offering 14
Microbiotica Spin Off from Wellcome Trust Sanger Institute 14
Wellcome Trust Sanger Institute – Key Competitors 15
Wellcome Trust Sanger Institute – Key Employees 16
Wellcome Trust Sanger Institute – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Strategy And Business Planning 18
Dec 19, 2016: Cambridge Innovation Capital and IP Group announce the creation of Wellcome Trust Sanger Institute spin-out company, Microbiotica 18
Dec 19, 2016: Cambridge Innovation Capital and IP Group announce the creation of Wellcome Trust Sanger Institute spin-out company, Microbiotica 20
Government and Public Interest 22
Jul 13, 2017: Largest study of malaria gene function reveals many potential drug targets 22
Mar 23, 2017: New stem cell method produces millions of human brain and muscle cells in days 23
Mar 03, 2017: Latest genomic technology uncovers secrets of immune system’s response to malaria 24
Feb 10, 2017: Malaria vaccine target’s invasion partner uncovered 25
Oct 18, 2016: Vulnerabilities of leukemia cells revealed using genome editing technique 26
Aug 01, 2016: Largest genomic study of heart disease in children reveals inherited genetic roots and new disorders 27
Mar 22, 2016: Genomes of chimpanzee parasite species reveal evolution of human malaria 29
Mar 14, 2016: Strongest single gene conclusively implicated in schizophrenia 31
Mar 07, 2016: Immunology meets single-cell sequencing 32
Product News 33
Dec 19, 2016: Genetic study of primary sclerosing cholangitis reveals potential drug target 33
Oct 19, 2017: Thermo Fisher Scientific and Wellcome Trust Sanger Institute Announce the Axiom Africa Array for Medical and Population Genomics 34
Other Significant Developments 35
Nov 09, 2017: Australia joins world-first Human Cell Atlas effort 35
Feb 08, 2016: Biogen Joins Pioneering Target Validation Collaboration 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Key Facts 2
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Wellcome Trust Sanger Institute, Deals By Therapy Area, 2011 to YTD 2017 8
Wellcome Trust Sanger Institute, Medical Devices Deals, 2011 to YTD 2017 9
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sigma-Aldrich Enters into Agreement with Sanger Institute 11
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 12
Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 13
Microbiotica Spin Off from Wellcome Trust Sanger Institute 14
Wellcome Trust Sanger Institute, Key Competitors 15
Wellcome Trust Sanger Institute, Key Employees 16
Wellcome Trust Sanger Institute, Other Locations 17

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Wellcome Trust Sanger Institute-製薬・医療分野:企業M&A・提携分析(Wellcome Trust Sanger Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆